Willy Adames to receive PRP treatment for sprained left elbow, with season status unclear

SAN FRANCISCO, Aug. 27, 2026 (Apex Times) - Willy Adames’ latest injury update centers on his left elbow, where the Giants shortstop is scheduled to receive a platelet-rich plasma (PRP) injection. The goal of the treatment is to address the sprain and reduce pain and inflammation, but Major League Baseball timelines around PRP vary, and the club’s own reporting suggests the process could be more than a short pause.

According to the Giants’ release, Adames was expected to get the PRP injection on Thursday. The team also cautioned that the procedure might put the shortstop on a path that ends his season. That framing matters because, at this point in the year, teams weigh whether they can afford to keep a high-leverage everyday player in a limited or uncertain availability window, or whether a longer recovery plan is the safer course.

The Giants’ update includes additional context: Adames received a second opinion from orthopedic specialist Dr. Keith Meister in Dallas. That consultation, per the report, did not result in a recommendation for surgery. In practical terms, it suggests the elbow issue is being managed without an immediate surgical intervention, at least based on that expert assessment, which can influence both recovery expectations and roster planning.

Elbow injuries among position players can be complicated because they often affect two crucial categories at once. First is discomfort during throwing, particularly for infielders who rely on quick, accurate releases and repeated hard throws across the season. Second is the hitting component, where elbow mechanics can influence bat speed and the ability to stay through contact. Even when surgery is avoided, PRP can be followed by a period of modified activity, building back tolerance gradually rather than all at once.

For the Giants, Adames’ health carries lineup implications beyond his personal performance. As the team’s shortstop, he is a central piece of its defensive structure and a key component of infield continuity. When a player at that position misses time, the club often has to adjust who anchors the left side of the infield, how ground balls are shaped, and how double-play turns are executed. Even a partial absence can force mid-season reshuffling that may not fully stabilize until the regular starter returns.

The PRP injection itself also raises questions about the plan’s next steps. A procedure that avoids surgery can still mean a measured rehabilitation schedule, with decisions about baseball activity dependent on symptoms and response to treatment. With the team already indicating the PRP could potentially end his season, the immediate watch item is not only whether Adames can return to fielding and hitting, but also whether his elbow can handle the intensity of game play without a setback.

Looking ahead, the next meaningful updates are likely to come in the form of activity progression and availability decisions, rather than dramatic milestones. If Adames responds as hoped, the Giants can regain their usual infield rhythm. If the elbow flare returns or the recovery timeline expands, the organization may need to plan for extended depth usage at shortstop and a steadier defensive workaround.

For now, the most concrete detail is the upcoming PRP treatment and the absence of a surgery recommendation from Dr. Meister. Whether that translates into a return before season’s end remains the central uncertainty, and it will shape how the Giants manage both roster flexibility and competitive goals in the final weeks of the campaign.